Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Catarina Craveiro, a biomedical research technician from Lisbon, had been hobbled by lower back pain from scoliosis since ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Multivitamin and cocoa extract supplements do not protect against clinical fractures for older adults, according to data ...

Atogepant vs placebo for the preventative treatment of migraine alleviated migraine symptoms across 3 clinical trials on day 1.

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

CNM-Au8 prolonged survival for people with ALS relative to those who received the investigational treatment zilucoplan or a ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Once daily treatment with Denali's oral candidate DNL343 failed to reduce NfL levels in adults with ALS in the HEALEY trial.

Treatment with deucravacitinib in patients with active PsA showed higher response rates and improvement in quality of life ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...